Key facts
- The Trump administration is pressuring European countries, including Germany, to increase their spending on medicines.
- U.S. embassies are actively involved in diplomatic efforts to secure bilateral drug pricing agreements.
- Germany is undergoing a healthcare system overhaul that includes drug pricing rules.
- Major pharmaceutical companies like Eli Lilly and Boehringer Ingelheim have reduced planned investments in Germany.
- The U.S. strategy involves country-by-country bilateral deals, exploiting Europe's fragmented health systems.
- The U.S. has threatened tariffs on pharmaceuticals and countries that do not comply.
The Trump administration is intensifying efforts across Europe to secure bilateral agreements on pharmaceutical drug pricing, aiming to persuade countries to increase their spending on medicines. U.S. embassies are reportedly mobilizing to deliver a message that European nations, particularly Germany, must contribute more to the cost of life-saving innovations, or risk losing out on future pharmaceutical investments and access to new drugs.
This strategy follows a recent deal with the U.K., which protected British pharmaceutical companies from U.S. tariffs for three years in exchange for increased drug spending over the next decade. U.S. diplomats are now targeting Germany, Europe's largest medicines market, which is currently overhauling its healthcare laws to cut federal spending on drugs. Washington is seeking to reverse this trend, engaging in confidential discussions with German Health Minister Nina Warken and Economic Affairs Minister Katherina Reiche regarding investments, trade policy, and fair pricing.
Industry figures suggest that Germany is envious of the U.K.-U.S. deal, as the pharmaceutical industry in Germany struggles to launch new drugs. This pressure comes as major companies like Eli Lilly and Boehringer Ingelheim have announced reductions in planned investments in Germany, citing the country's cost-cutting measures. Some stalled investments in the U.K. were reportedly resumed after the drug pricing deal was struck.
However, European governments are hesitant to follow the U.K.'s lead, citing squeezed public finances and sluggish economic growth. They are also skeptical that conceding to the pharmaceutical industry will end the pressure campaign. Furthermore, the U.S. faces challenges in negotiating with EU countries due to trade policy being an EU competence, while drug pricing remains largely national. The U.S. has threatened tariffs on pharmaceuticals and countries, with a 15 percent tariff already set for EU nations. The U.S. administration is also leveraging its most-favored nation (MFN) drug pricing policy, which will match the lowest drug prices from a basket of wealthy countries, including Germany, potentially impacting product launches in those markets.